FDA clears new drug-eluting envelope for implantable cardiac devices—CEO sees it as ‘tip of the iceberg’ Posted on June 20th, 2024 by Betsy Stovsky Post navigation Previous: ABBOTT RECEIVES CE MARK FOR AVEIR™ DR, THE WORLD’S FIRST DUAL CHAMBER LEADLESS PACEMAKER SYSTEMNext: Biotronik receives CE mark for Amvia Sky and Edge devices
Abbott receives CE mark for Aveir dual chamber leadless pacemaker system Posted on June 6th, 2024 by LEADconnection Post navigation Previous: CIED Infection Quality Initiative Demonstration Project (RECTIFY)Next: ABBOTT RECEIVES CE MARK FOR AVEIR™ DR, THE WORLD’S FIRST DUAL CHAMBER LEADLESS PACEMAKER SYSTEM
HRS 2024: Small diameter defibrillation lead meets safety and effectiveness endpoints in LEADR trial Posted on May 23rd, 2024 by LEADconnection Post navigation Previous: Atrial lead perforation early after device implantation-a case report and literature reviewNext: Cardiac implantable electronic device-induced tricuspid regurgitation: Implications and management.